{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:21:40Z","timestamp":1790918500681,"version":"4.1.0"},"reference-count":53,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T00:00:00Z","timestamp":1341360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Worldwide, 50\u201370\u2003million subjects are infected with an hepatitis C virus (HCV) genotype 2, 3, 4, 5 or 6. In these patients, the combination of PEG\u2010INF\u2010\u03b1 and ribavirin remains the currently approved standard\u2010of\u2010care treatment. The identification of different potential therapeutic targets in the HCV life cycle has led to the development of both direct antiviral agents (DAAs) and reagents targeting host functions essential for viral replication. DAAs comprise so far first\u2010generation, second\u2010wave and second\u2010generation NS3\/4A protease inhibitors (PIs), nucleos(t)ide (NIs) and non\u2010nucleoside inhibitors of the NS5B RNA polymerase and NS5A complex inhibitors. The main host\u2010protein\u2010directed antiviral agents are cyclophilin inhibitors and silibinin. Whereas the launch of first\u2010generation PIs was a major landmark in the management of genotype 1 (GT\u20101)\u2010infected patients, these drugs are inactive in most non\u2010GT\u20101\u2010infected patients. Several of these and other drugs have now reached phase II and even phase III clinical stage development. The purpose of this article is to provide an overview of the clinical results recently reported for the treatment for non\u2010GT\u20101 HCV infection with a focus on the most promising new compounds and combinations.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2012.01634.x","type":"journal-article","created":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T07:33:03Z","timestamp":1341473583000},"page":"525-536","source":"Crossref","is-referenced-by-count":20,"title":["Hepatitis C therapy in non\u2010genotype 1 patients: the near future"],"prefix":"10.1111","volume":"19","author":[{"given":"C.","family":"Wartelle\u2010Bladou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Le Folgoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bourli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,4]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014463"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24480"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.056"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.02.009"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24154"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.07.041"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.05.079"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.11.016"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.07.019"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.09.008"},{"key":"e_1_2_8_17_2","first-page":"810A","article-title":"An optimal duration of treatment for chronic hepatitis C genotype 6 patients","volume":"54","author":"Pham TTT","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01566.x"},{"key":"e_1_2_8_19_2","first-page":"824A","article-title":"Worldwide experience treating chronic hepatitis C with peginterferon alfa\/ribavirin: final results from 7163 naive mono\u2010infected patients enrolled in the large multinational PROPHESYS cohort study","volume":"54","author":"Marcellin P","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1282072"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.05.046"},{"key":"e_1_2_8_22_2","unstructured":"SilvaM KasserraC GuptaA TreitelM HughesE O\u2019MaraE.Antiviral activity of boceprevir monotherapy in treatment\u2010naive subjects with chronic hepatitis C genotype 2\/3. APASL Feb 17\u201320 2011. Available at:http:\/\/www.natap.org\/2011\/APSL\/APSL_03.htm."},{"key":"e_1_2_8_23_2","first-page":"719A","article-title":"Activity of telaprevir or in combination with peginterferon alfa\u20102a and ribavirin in treatment naive genotype 4 hepatitis C patients. Final results of study C210","volume":"52","author":"Benhamou Y","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.004"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01058-08"},{"issue":"1","key":"e_1_2_8_26_2","first-page":"99","article-title":"MK\u20105172, a next generation HCV NS3\/4A protease inhibitor is active against common resistance associated variants (RAVS) and exhibits cross genotype activity","volume":"7","author":"Barnard RJ","year":"2011","journal-title":"Global Antiviral Journal"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2011.05.003"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2011.05.010"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21102"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.072"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)61362-7"},{"key":"e_1_2_8_33_2","first-page":"993A","article-title":"Pegylated interferon lambda ameliorates ribavirin\u2010induced anemia in HCV patients by maintaining compensatory erythropoiesis: analysis of emerge phase 2B results through week 12","volume":"54","author":"Everson GT","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_8_34_2","first-page":"994A","article-title":"Safety and efficacy of pegylated interferon lambda compared to pegylated interferon alfa\u20102A in HCV\u2010infected patients G1\/2\/3 with compensated cirrhosis: EMERGE phase 2b efficacy and safety results through week 12","volume":"54","author":"Rodriguez\u2010Torres M","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i47.5184"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.033"},{"key":"e_1_2_8_37_2","first-page":"531A","article-title":"Safety and antiviral activity of MK\u20105172, a next generation HCV NS3\/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants in genotype 1 and 3 HCV infected patients","volume":"54","author":"Peltry AS","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(10)60039-6"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)60063-9"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61125-8"},{"key":"e_1_2_8_41_2","first-page":"377A","article-title":"Once daily PSI\u20107977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment naive patients with HCV GT2 or GT3","volume":"54","author":"Gane EJ","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22835"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.217323"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61416-0"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61433-0"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60024-5"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61189-1"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61225-2"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61217-3"},{"key":"e_1_2_8_50_2","first-page":"57","article-title":"PSI\u20107977 with PEG\/RBV elicits rapid declines in HCV RNA in patients with HCV GT\u20104 and GT\u20106","volume":"7","author":"Hassanein T","year":"2011","journal-title":"GAJ"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)00243-7"},{"key":"e_1_2_8_52_2","first-page":"474A","article-title":"BMS\u2010790052, A NS5A replication complec inhibitor combined with peginterferon alfa 2a and ribavirin in treatment naive HCV\u2010genotype 1 or 4 patients: phase 2B AI444010 study interim week 12 results","volume":"54","author":"Hezode C","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2011.05.008"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31800-9"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2012.01634.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2012.01634.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:20:03Z","timestamp":1698639603000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2012.01634.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,4]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1365-2893.2012.01634.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2012.01634.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,4]]}}}